Literature DB >> 20979567

Personalized cancer vaccines.

Kewal K Jain1.   

Abstract

IMPORTANCE OF THE FIELD: Personalized medicine has extended to management of cancer and implies prescription of specific therapeutics best suited for an individual patient and the type of tumor. These principles have been applied to cancer vaccines. AREAS COVERED IN THIS REVIEW: Various cancer vaccines that can be personalized. Tumor-derived vaccines have been used and active immunotherapy based on antigens specific to the tumor. Dendritic cells (DCs) can prime tumor-specific T cell responses and are considered potentially effective vaccines for cancer. DCs may be genetically modified or fused with tumor cells. Adoptive cell therapy is based on autologous antigen-specific T lymphocytes. Personalized peptide vaccination has been combined with chemotherapy. Clinical trials have been conducted. There have been many failures but a selection of those currently in progress is presented. WHAT THE READER WILL GAIN: An overview of various types of personalized cancer vaccines, their mechanism of action and current status of development. Causes of failure of clinical trials and concepts of an ideal personalized cancer vaccine are presented. TAKE HOME MESSAGE: A number of approaches are available for personalized cancer vaccines with variable degree of success. There are several challenges and needs for refinement of methods but it remains a promising area of cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979567     DOI: 10.1517/14712598.2010.531256

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  5 in total

1.  MYCN: from oncoprotein to tumor-associated antigen.

Authors:  Vito Pistoia; Fabio Morandi; Annalisa Pezzolo; Lizzia Raffaghello; Ignazia Prigione
Journal:  Front Oncol       Date:  2012-11-16       Impact factor: 6.244

2.  The evolutionary significance of certain amino acid substitutions and their consequences for HIV-1 immunogenicity toward HLA's A*0201 and B*27.

Authors:  Luke Hecht; Anton Dormer
Journal:  Bioinformation       Date:  2013-03-19

Review 3.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

Review 4.  When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy.

Authors:  Linna Yu; Yi Jin; Mingjie Song; Yu Zhao; Huaqing Zhang
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

5.  Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.

Authors:  Genevieve M Weir; Robert S Liwski; Marc Mansour
Journal:  Cancers (Basel)       Date:  2011-08-05       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.